Improvement in Lung Clearance Index and Chest CT Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Study.
primary studies published, non RCT
Details- 2023
- McNally P
Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.
primary studies published, non RCT
Details- 2023
- Grancini V
Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data.
primary studies published, non RCT
Details- 2023
- Granger E
Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.
primary studies published, non RCT
Details- 2023
- McElvaney OJ
Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease.
primary studies published, non RCT
Details- 2023
- Siegel MJ
Newborn screening alone insufficient to improve pulmonary outcomes for cystic fibrosis.
primary studies published, non RCT
Details- 2021
- Barreda CB
Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis.
primary studies published, non RCT
Details- 2022
- Berg P
The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data.
primary studies published, non RCT
Details- 2022
- Granger E
Feasibility and acceptability of a CF-specific cognitive-behavioral preventive intervention for adults integrated into team-based care.
primary studies published, non RCT
Details- 2022
- Friedman D
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.
primary studies published, non RCT
Details- 2022
- Gold LS